1. Scrip
  2. >>Business
  3. >>Financing

Nested Therapeutics Targets Mutations Hiding In Plain Sight

 
• By Alaric DeArment

Newly launched with a $90m series A funding round, the company is taking the idea behind KRAS G12C inhibitors to another level.

Nested Therapeutics launched with a $90m series A funding round • Source: Shutterstock

With the US Food and Drug Administration’s 2021 accelerated approval of Amgen, Inc.’s Lumakras (sotorasib) as the first-ever inhibitor of the “undruggable” target KRAS G12C, a number of companies – notably Mirati Therapeutics, Inc. – have sought to bring their own drugs with the same target to market. But the newly launched Nested Therapeutics is hoping to take the same underlying principle beyond that one target.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.